This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification
NameActeoside
Accession NumberDB12996
TypeSmall Molecule
GroupsInvestigational
Description

Acteoside is under investigation in clinical trial NCT02662283 (Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy).

Structure
Thumb
SynonymsNot Available
External IDs TJC-160
Product Ingredients Not Available
ProductsNot Available
International BrandsNot Available
Brand mixturesNot Available
Categories
UNII3TGX09BD5B
CAS number61276-17-3
WeightAverage: 624.5871
Monoisotopic: 624.205420482
Chemical FormulaC29H36O15
InChI KeyFBSKJMQYURKNSU-ZLSOWSIRSA-N
InChI
InChI=1S/C29H36O15/c1-13-22(36)23(37)24(38)29(41-13)44-27-25(39)28(40-9-8-15-3-6-17(32)19(34)11-15)42-20(12-30)26(27)43-21(35)7-4-14-2-5-16(31)18(33)10-14/h2-7,10-11,13,20,22-34,36-39H,8-9,12H2,1H3/b7-4+/t13-,20+,22-,23+,24+,25+,26+,27+,28+,29-/m0/s1
IUPAC Name
(2R,3R,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-5-hydroxy-2-(hydroxymethyl)-4-{[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}oxan-3-yl (2E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
SMILES
Pharmacology
IndicationNot Available
Structured Indications Not Available
PharmacodynamicsNot Available
Mechanism of actionNot Available
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organismsNot Available
PathwaysNot Available
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Acteoside.Approved
BCG vaccineThe therapeutic efficacy of Bcg can be decreased when used in combination with Acteoside.Investigational
BevacizumabBevacizumab may increase the cardiotoxic activities of Acteoside.Approved, Investigational
CabazitaxelThe risk or severity of adverse effects can be increased when Cabazitaxel is combined with Acteoside.Approved
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Acteoside.Approved, Investigational
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Acteoside.Approved
DeslanosideDeslanoside may decrease the cardiotoxic activities of Acteoside.Approved
DigitoxinDigitoxin may decrease the cardiotoxic activities of Acteoside.Approved
DigoxinDigoxin may decrease the cardiotoxic activities of Acteoside.Approved
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Acteoside.Approved, Investigational
FingolimodActeoside may increase the immunosuppressive activities of Fingolimod.Approved, Investigational
G17DTThe risk or severity of adverse effects can be increased when Acteoside is combined with G17DT.Investigational
GI-5005The risk or severity of adverse effects can be increased when Acteoside is combined with GI-5005.Investigational
INGN 201The risk or severity of adverse effects can be increased when Acteoside is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Acteoside is combined with INGN 225.Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Acteoside is combined with Leflunomide.Approved, Investigational
NatalizumabThe risk or severity of adverse effects can be increased when Acteoside is combined with Natalizumab.Approved, Investigational
OleandrinAnvirzel may decrease the cardiotoxic activities of Acteoside.Experimental
OuabainOuabain may decrease the cardiotoxic activities of Acteoside.Approved
PaclitaxelThe risk or severity of adverse effects can be increased when Paclitaxel is combined with Acteoside.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Acteoside.Approved, Investigational
Rabies virus inactivated antigen, AThe risk or severity of adverse effects can be increased when Acteoside is combined with Rabies vaccine.Approved
Rabies virus inactivated antigen, AThe therapeutic efficacy of Rabies vaccine can be decreased when used in combination with Acteoside.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Acteoside is combined with CDX-110.Investigational
RoflumilastRoflumilast may increase the immunosuppressive activities of Acteoside.Approved
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Acteoside.Approved
SRP 299The risk or severity of adverse effects can be increased when Acteoside is combined with SRP 299.Investigational
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Acteoside.Approved, Investigational
TG4010The risk or severity of adverse effects can be increased when Acteoside is combined with TG4010.Investigational
TofacitinibActeoside may increase the immunosuppressive activities of Tofacitinib.Approved, Investigational
TrastuzumabTrastuzumab may increase the cardiotoxic activities of Acteoside.Approved, Investigational
Food InteractionsNot Available
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Properties
StateNot Available
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.966 mg/mLALOGPS
logP1.09ALOGPS
logP0.82ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)9.01ChemAxon
pKa (Strongest Basic)-3.6ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count14ChemAxon
Hydrogen Donor Count9ChemAxon
Polar Surface Area245.29 Å2ChemAxon
Rotatable Bond Count11ChemAxon
Refractivity148.4 m3·mol-1ChemAxon
Polarizability60.62 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability0ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET featuresNot Available
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of chemical entities known as coumaric acids and derivatives. These are aromatic compounds containing Aromatic compounds containing a cinnamic acid moiety (or a derivative thereof) hydroxylated at the C2 (ortho-), C3 (meta-), or C4 (para-) carbon atom of the benzene ring.
KingdomChemical entities
Super ClassOrganic compounds
ClassPhenylpropanoids and polyketides
Sub ClassCinnamic acids and derivatives
Direct ParentCoumaric acids and derivatives
Alternative ParentsCinnamic acid esters / O-glycosyl compounds / Disaccharides / Tyrosols and derivatives / Styrenes / Catechols / 1-hydroxy-2-unsubstituted benzenoids / 1-hydroxy-4-unsubstituted benzenoids / Fatty acid esters / Oxanes
SubstituentsCoumaric acid or derivatives / Cinnamic acid ester / Disaccharide / Glycosyl compound / O-glycosyl compound / Tyrosol derivative / Catechol / Styrene / 1-hydroxy-4-unsubstituted benzenoid / 1-hydroxy-2-unsubstituted benzenoid
Molecular FrameworkAromatic heteromonocyclic compounds
External Descriptorshydroxycinnamic acid (CHEBI:9953 )
Drug created on October 20, 2016 19:53 / Updated on September 01, 2017 12:27